# Abaloparatide Real-World Patient Experience Study.

> PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33778325-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33778325-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33778325-abaloparatide-v1.json
- Content SHA-256: `29aefe969c3c8a109beec738d5662337f8e3ad3fd077c06484b128a1e00cdec0`

## Claims and source pins

### Headline

Abaloparatide Real-World Patient Experience Study. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

### Summary

PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

### Paragraph 1

PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`](#source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e))

## Sources

<a id="source-pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e"></a>
- **Abaloparatide Real-World Patient Experience Study. · retained source version 1:2021-03-30:current:951f8ae1283eff3af0ca47104ad81ab12cf661211168394edc09d1a2de7504cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33778325/) (`pubmed-observation-pmid-33778325-2021-03-30-951f8ae1283e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Abaloparatide Real-World Patient Experience Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33778325-abaloparatide-v1.json SHA-256: 29aefe969c3c8a109beec738d5662337f8e3ad3fd077c06484b128a1e00cdec0.